THE SURFACTANT POSITIVE AIRWAY PRESSURE AND PULSE OXIMETRY TRIAL

表面活性剂气道正压和脉搏血氧饱和度试验

• 批准号: 8166603
• 负责人: KRISTI L. WATTERBERG
• 金额: $ 3.54万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166603
• 关键词: Air; Air Pressure; Birth; Blindness; Blood; Borderline Personality Disorder; Breathing; Bronchopulmonary Dysplasia; Chronic lung disease; Computer Retrieval of Information on Scientific Projects Database; Continuous Positive Airway Pressure; Eye diseases; Funding; Grant; Guidelines; Infant; Institution; Intubation; Lung; Medicine; Oxygen; Premature Infant; Pulse Oximetry; Research; Research Personnel; Resources; Retinopathy of Prematurity; Risk; Source; Tube; United States National Institutes of Health; Vision; pressure; surfactant

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This research asks two basic questions: which of two lung treatments in premature babies is better for the baby?s lungs; and what is the appropriate level of oxygen in premature infants blood. The two lung treatments are 'CPAP' (positive air pressure to help keep the lungs inflated) and 'intubation,' placement of a breathing tube in the infant?s airway with administration of surfactant through this breathing tube. Regardless of which treatment is used, all babies who need help with breathing are at risk of developing a type of chronic lung disease called 'Bronchopulmonary Dysplasia,' or 'BPD'. Since 1990, surfactant has been available to help premature babies breathe easier, but they must be intubated to give this medicine. Oxygen is also given whenever a baby is not able to get enough oxygen into his/her blood by breathing room air. It is important not to give too much oxygen because too much oxygen may cause an eye disease called 'Retinopathy of Prematurity,' or 'ROP,' that may result in poor vision or even blindness. In this study, infants who receive CPAP and who have specific guidelines for intubation will be compared to infants who are intubated and are given surfactant soon after birth. The study also compares a lower range (85-89%) and higher range (91-95%) of oxygen levels in the blood. It is known that higher oxygen ranges are associated with eye disease, however, the safest oxygen range is still unknown. We hope to find out if a lower range results in less ROP.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项研究提出了两个基本问题：早产儿的两种肺部治疗中哪一种对婴儿的肺部更好？早产儿血液中的适当含氧量是多少。两种肺部治疗方法是“CPAP”（正气压帮助保持肺部充气）和“插管”，即在婴儿气道中放置一根呼吸管，并通过该呼吸管施用表面活性剂。 无论使用哪种治疗方法，所有需要呼吸帮助的婴儿都有患上一种称为“支气管肺发育不良”或“BPD”的慢性肺部疾病的风险。 自 1990 年以来，表面活性剂已可帮助早产儿呼吸更顺畅，但必须插管才能给予这种药物。 当婴儿无法通过呼吸室内空气将足够的氧气带入血液时，也会给予氧气。 重要的是不要给予过多的氧气，因为过多的氧气可能会导致一种称为“早产儿视网膜病变”或“ROP”的眼部疾病，从而导致视力不佳甚至失明。 在这项研究中，接受 CPAP 且有具体插管指南的婴儿将与出生后不久插管并给予表面活性剂的婴儿进行比较。该研究还比较了血液中较低范围（85-89%）和较高范围（91-95%）的氧气水平。 众所周知，较高的氧气范围与眼部疾病有关，但最安全的氧气范围仍然未知。 我们希望了解较低的范围是否会导致 ROP 降低。